Gulf Pharmaceutical Industries P.S.C.

ADX:JULPHAR Rapporto sulle azioni

Cap. di mercato: د.إ1.5b

Gulf Pharmaceutical Industries P.S.C Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Basel Nimer Ziyadeh

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO1.8yrs
Proprietà del CEOn/a
Durata media del management3.5yrs
Durata media del Consiglio di amministrazione4.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Oct 16
Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Jan 15
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Nov 04
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Mar 26
Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Feb 08
Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

Dec 14
Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

AMMINISTRATORE DELEGATO

Basel Nimer Ziyadeh

1.8yrs

Mandato

Mr. Basel Nimer Ali Ziyadeh is Chief Executive Officer of Gulf Pharmaceutical Industries P.S.C. from February 2023. Mr. Basel was CEO for Tabuk Pharmaceuticals, where he was instrumental in transforming th...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Basel Nimer Ziyadeh
Chief Executive Officer1.8yrsNessun datoNessun dato
Ignacio Anglada
Chief Financial Officer2.3yrsNessun datoNessun dato
Malik Metahri
Chief Technical Officer1.8yrsNessun datoNessun dato
Adel Khalaf
General Counsel & Chief Compliance Officer4.8yrsNessun datoNessun dato
Hosam Badr
Marketing Director10.7yrsNessun datoNessun dato
Juergen Lauterbach
Chief Corporate Development & Strategy Officer2.3yrsNessun datoNessun dato
Gopa Kumar
Chief Human Resources Officer4.8yrsNessun datoNessun dato
Amgad Thabet
Chief Commercial Officer4.8yrsNessun datoNessun dato
Rayan Omer
Company Secretaryno dataNessun datoNessun dato

3.5yrs

Durata media

Gestione esperta: Il team dirigenziale di JULPHAR è considerato esperto (durata media dell'incarico 3.5 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Abdulaziz Al Zaabi
Director7.8yrsNessun datoNessun dato
Rabih Khouri
Vice-Chairman of the Board3.3yrsNessun datoNessun dato
Raman Garg
Independent Director4.7yrsNessun datoNessun dato
Jean Diab
Director1.6yrsNessun datoNessun dato
Saqer Bin Al Qassimi
Chairman of the Board19.8yrsNessun datoNessun dato
Medhat Mohamed Al Gamal
Director5.8yrsNessun datoNessun dato
Abboud Bejjani
Director4.8yrsNessun datoNessun dato
Olfa Gam
Director3.3yrsNessun datoNessun dato
Hamodi Abas Al limy
Director2.4yrsNessun datoNessun dato

4.7yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di JULPHAR sono considerati esperti (durata media dell'incarico 4.7 anni).